179 related articles for article (PubMed ID: 8223830)
1. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Wolffenbuttel BH; Nijst L; Sels JP; Menheere PP; Müller PG; Kruseman AC
Eur J Clin Pharmacol; 1993; 45(2):113-6. PubMed ID: 8223830
[TBL] [Abstract][Full Text] [Related]
2. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
Landgraf R; Bilo HJ; Müller PG
Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Mafauzy M
Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Van Gaal LF; Van Acker KL; De Leeuw IH
Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
[TBL] [Abstract][Full Text] [Related]
6. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Wolffenbuttel BH; Landgraf R
Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
8. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
9. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide versus glyburide: a one-year comparison trial.
Marbury T; Huang WC; Strange P; Lebovitz H
Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide as monotherapy in Type 2 diabetes.
Gomis R
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S133-5. PubMed ID: 10522838
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
Wolffenbuttel BH
Neth J Med; 1999 Nov; 55(5):229-34. PubMed ID: 10593133
[TBL] [Abstract][Full Text] [Related]
15. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
[TBL] [Abstract][Full Text] [Related]
16. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Rutten GE
Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
[TBL] [Abstract][Full Text] [Related]
17. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Esposito K; Giugliano D; Nappo F; Marfella R;
Circulation; 2004 Jul; 110(2):214-9. PubMed ID: 15197140
[TBL] [Abstract][Full Text] [Related]
18. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
19. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
